Krüppel-like factor 15 (KLF15) small molecule agonists in kidney disease
AssigneesThe United States Government as represented by the Department of Veterans Affairs, Icahn School of Medicine at Mount Sinai, The Research Foundation for The State University of New York
InventorsSandeep Mallipattu, Bhaskar Das
Life of this patent
Estimating the term…
Abstract
The present disclosure is concerned with small molecule modulators of KLF15 signaling useful for treating various disorders such as, for example, kidney disease (e.g., chronic kidney disease), heart disease, obesity, or a neurodegenerative disorder (e.g., amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Claims8
A compound having a structure represented by a formula:
- wherein Z1 is CR2b and Z2 is CR2c;
- wherein R1 is linear or branched C1-C4 alkyl;
- wherein each of R2a, R2b, R2c, R2d, R3a, and R3b is independently selected from hydrogen and halogen;
- wherein each of R3c and R3d is independently selected from hydrogen and halogen;
- wherein R8 is selected from —B(OR11)2 and —B(R12)3;
- wherein each occurrence of R11 is independently selected from hydrogen and linear or branched C1-C8 alkyl,
- or wherein each occurrence of R11 is covalently bonded together, and, together with the intermediate atoms, comprise a structure:
- and is substituted with 0, 1, 2, 3, or 4 linear or branched C1-C4 alkyl groups;
- and
- wherein each occurrence of R12 is independently halogen,
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.